Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis
Barraco, Fiorenza; Greil, Richard; Herbrecht, Raoul; Schmidt, Burkhard; Reiter, Andreas; Willenbacher, Wolfgang; Raymakers, Reinier; Liersch, Rüdiger; Wroclawska, Monika; Pack, Robert; Burock, Karin; Karumanchi, Divyadeep; Gisslinger, Heinz
(2020) British Journal of Haematology, volume 191, issue 5, pp. 764 - 774
(Article)
Abstract
Primary objective of this non-interventional, post-authorisation safety study was to provide real-world safety data [incidence of adverse drug reactions (ADRs)/serious adverse events (SAEs)] on adult patients with myelofibrosis exposed/or not exposed to ruxolitinib. Key secondary objectives included the incidence/outcome of events of special interest (bleeding events, serious/opportunistic infections, second primary
... read more
malignancies, and deaths). Overall, 462 patients were included [prevalent users = 260, new users = 32, non-exposed = 170 (inclusive of ruxolitinib-switch, n = 57)]. The exposure-adjusted incidence rates (per 100 patient-years) of ADRs (19·3 vs. 19·6) and SAEs (25·2 vs. 25·0) were comparable amongst new-users versus prevalent-users cohorts, respectively; most frequent ADRs across all cohorts included thrombocytopenia, anaemia, epistaxis, urinary tract infection, and herpes zoster. Anaemia, pneumonia, general physical health deterioration, sepsis, and death were the most frequent SAEs across all cohorts. Incidence rates of bleeding events (21·6) and serious/opportunistic infections (34·5) were higher in ruxolitinib-switch cohort versus other cohorts. The incidence rate of second primary malignancies was higher in the prevalent-users cohort (10·1) versus other cohorts. The observed safety profile of ruxolitinib in the present study along with the safety findings from the COMFORT/JUMP/EXPAND studies support the use of ruxolitinib for long-term treatment of patients with myelofibrosis.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: adverse drug reaction, adverse event, myelofibrosis, ruxolitinib, safety, Hematology, Journal Article
ISSN: 0007-1048
Publisher: Wiley-Blackwell
Note: Funding Information: The authors would like to thank Michael Levine (Senior Global Program Safety Team Lead, Novartis Pharmaceuticals Corp., East Hanover, NJ, USA) and Satish Mahadevaiah Chandraiah (Global Program Safety Lead, Novartis Healthcare Pvt Ltd, Hyderabad, India) for their contribution to the data analysis, and Vijay Kadasi (Senior Scientific Writer II, Novartis Healthcare Pvt Ltd, Hyderabad) for medical writing assistance with this manuscript. This work was supported by Novartis Pharmaceuticals Corp., East Hanover, NJ, USA. Funding Information: The authors would like to thank Michael Levine (Senior Global Program Safety Team Lead, Novartis Pharmaceuticals Corp., East Hanover, NJ, USA) and Satish Mahadevaiah Chandraiah (Global Program Safety Lead, Novartis Healthcare Pvt Ltd, Hyderabad, India) for their contribution to the data analysis, and Vijay Kadasi (Senior Scientific Writer II, Novartis Healthcare Pvt Ltd, Hyderabad) for medical writing assistance with this manuscript. This work was supported by Novartis Pharmaceuticals Corp., East Hanover, NJ, USA. Publisher Copyright: © 2020 British Society for Haematology and John Wiley & Sons Ltd
(Peer reviewed)